Cassava's Alzheimer's drug fails in late-stage study
Nov 25 (Reuters) - Cassava Sciences SAVA.O on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals in a late-stage study. (Reporting by Bhanvi Satija in Bengaluru; Editing by Tasim Zahid) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))